CollPlant Biotechnologies Ltd.
NASDAQ: CLGN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yehiel Tal
- Employees
- 57
- Headquarters
- Rehovot, Israel
- IPO year
- 2018
- Market cap
- $4.1M
- Website
- https://www.collplant.com
Loading CLGN…
Loading profile data…Frequently asked questions about CLGN
What does CollPlant Biotechnologies Ltd. (CLGN) do?
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside developing solutions for medical aesthetics. All of CollPlant's offerings are underpinned by its propri...
Where does CLGN trade?
CollPlant Biotechnologies Ltd. (CLGN) trades on the NASDAQ Global Market.
What sector is CLGN in?
CollPlant Biotechnologies Ltd. (CLGN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CollPlant Biotechnologies Ltd.?
Yehiel Tal is the chief executive officer of CollPlant Biotechnologies Ltd. (CLGN).
Where is CollPlant Biotechnologies Ltd. headquartered?
CollPlant Biotechnologies Ltd. is headquartered in Israel.
Does CLGN pay a dividend?
CollPlant Biotechnologies Ltd. (CLGN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CLGN go public?
CollPlant Biotechnologies Ltd. (CLGN) completed its initial public offering in 2018.
Is CLGN an ADR?
Yes — CLGN is an American Depositary Receipt; its underlying shares trade on a non-US exchange. CollPlant Biotechnologies Ltd. reporting and dividends follow the underlying issuer.